Pictet Asset Management (Switzerland)’s BridgeBio Pharma BBIO Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$43.6M	Buy	2,532,716 +1,090,284	+76%	+$16.4M	0.05%	315
2023 Q1	$23.9M	Buy	1,442,432 +901,628	+167%	+$10.5M	0.03%	426
2022 Q4	$4.12M	Buy	540,804 +142,039	+36%	+$1.36M	0.01%	782
2022 Q3	$3.96M	Buy	398,765 +110,107	+38%	+$1.14M	0.01%	783
2022 Q2	$2.62M	Buy	288,658 +196,988	+215%	+$1.65M	﹤0.01%	895
2022 Q1	$930K	Hold	91,670	–	–	﹤0.01%	1063
2021 Q4	$1.53M	Buy	91,670 +22,599	+33%	+$956K	﹤0.01%	1025
2021 Q3	$3.24M	Buy	+69,071	New	+$3.7M	﹤0.01%	925

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s BBIO Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) increased its BridgeBio Pharma (BBIO) stake by 76% in Q2 2023, buying an estimated $16.4M and bringing the position to 2,532,716 shares worth $43.6M. The position accounts for 0.05% of the portfolio, ranked #315.

Pictet Asset Management (Switzerland) first reported a position in BBIO in Q3 2021 and has held it in 8 quarters since. 197 funds tracked by Wall St. Rank hold BBIO as of Q2 2023.

Pictet Asset Management (Switzerland) held 2,532,716 shares of BridgeBio Pharma worth $43.6M as of Q2 2023.
Pictet Asset Management (Switzerland) bought 1,090,284 BridgeBio Pharma shares in Q2 2023, an estimated $16.4M.
BridgeBio Pharma made up 0.05% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #315 holding.
Pictet Asset Management (Switzerland) first reported a position in BridgeBio Pharma in Q3 2021 and has held it in 8 quarters since.
197 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.